It was reported on Thursday that United States-based BioMarin has named Maykin Ho, PhD, as its new director.
Dr Ho has over 30 years of experience in the healthcare and finance industries. She is serving on the boards of Agios Pharmaceuticals Inc, FibroGen Inc, Grail Inc, Parexel, the Aaron Diamond AIDS Research Center, and the Institute for Protein Innovation. She is a venture partner of Qiming Venture Partners and a member of the Biotech Advisory Panel of the Stock Exchange of Hong Kong. She has served in Goldman Sachs Group, DuPont-Merck Pharmaceuticals and DuPont de Nemours & Company.
Jean-Jacques Bienaime, chairman and CEO at BioMarin, said, 'We are thrilled to welcome Maykin to BioMarin's board of directors. She brings a breadth and depth of experience in the healthcare industry and finance to an already exceptional board. Maykin brings an important perspective to support BioMarin's growth trajectory as we strive to address the unmet medical needs of people affected by rare genetic diseases and deliver scientific breakthroughs.'
Biller Named to Rome Therapeutics Board of Directors
Beck Named Chief Financial Officer at 4D Pharma
Gyroscope Therapeutics names Jessica Stitt as CFO
Campanelli Named to Slayback Board of Directors
Zhang Named Chief Medical Officer at InnoCare
The University of Health Sciences and Pharmacy in St Louis names new president
New COVID-19 virus variant discovered in New York City and Northeast US
NovellusDx Establishes Fore Biotherapeutics US as its Operating company in the United States
Dhingra Named Chairman of the Board of Directors at Lava Therapeutics